Sponsor:
Alnylam Pharmaceuticals
Code:
NCT07358078
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Transthyretin Amyloidosis With Cardiomyopathy
Study ID
NCT07358078
Start date
Jan 9, 2026
Status verified date
Sep, 2026
Completion date
Oct 23, 2030
Anticipated
Primary completion date
Oct 23, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
2000 participants
Anticipated
Arms
Patients with ATTR-CM
Primary outcome measure
Central contacts
Locations
Clinical Trial Site
Recruiting
Tucson, Arizona, United States, 85711
Clinical Trial Site
Recruiting
Beverly Hills, California, United States, 90211
Clinical Trial Site
Recruiting
Naples, Florida, United States, 34102
Clinical Trial Site
Recruiting
Kansas City, Kansas, United States, 66160
Clinical Trial Site
Recruiting
Boston, Massachusetts, United States, 02215
Clinical Trial Site
Recruiting
St Louis, Missouri, United States, 63110
Clinical Trial Site
Recruiting
New Brunswick, New Jersey, United States, 08901
Clinical Trial Site
Recruiting
Charlotte, North Carolina, United States, 28270
Clinical Trial Site
Recruiting
Philadelphia, Pennsylvania, United States, 19104
Clinical Trial Site
Recruiting
Memphis, Tennessee, United States, 38120
Clinical Trial Site
Recruiting
Dallas, Texas, United States, 75390
Sponsor
Alnylam Pharmaceuticals
Last update posted
Sep 9, 2026
Last verified
Sep, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Alnylam Pharmaceuticals on 2026-09-09.